Investing

Immunovant : IMVT

IMVT

Stock Data

$27.12

$0.03 (0.09%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Immunovant Inc is a New York-based biopharmaceutical company focused on developing innovative treatments for autoimmune diseases. Its main project, batoclimab, is a groundbreaking antibody aimed at conditions like myasthenia gravis, thyroid eye disease, and several others. As part of the Roivant Sciences family, Immunovant is at the forefront of addressing unmet medical needs in the autoimmune space.

All Immunovant Articles

1 Article

Trey Thoelcke | Dec 17, 2025 at 8:45 AM EST

Share Offerings Prompt Huge Insider Buying in These 3 Biotechs

Secondary offerings from biotechs Immunovant, Kymera Therapeutics, and Wave Life Sciences prompted some huge insider buying recently.